APC is altered in 2.2% of medulloblastoma patients [3].

APC is an inclusion criterion in 7 clinical trials for medulloblastoma, of which 7 are open and 0 are closed. Of the trials that contain APC status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

APC is an inclusion criterion in 3 clinical trials for familial adenomatous polyposis, of which 2 are open and 1 is closed. Of the trials that contain APC status and familial adenomatous polyposis as inclusion criteria, 1 is phase 2 (1 open) and 2 are phase 3 (1 open) [4].

APC is an inclusion criterion in 3 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 3 are open and 0 are closed. Of the trials that contain APC status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

APC is an inclusion criterion in 3 clinical trials for medulloblastoma, WNT-activated, of which 3 are open and 0 are closed. Of the trials that contain APC status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

APC is altered in 5.26% of desmoplastic/nodular medulloblastoma patients [3].

APC is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

APC is altered in 3.88% of anaplastic astrocytoma patients [3].

APC is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain APC status and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (1 open) [4].

APC is altered in 3.04% of glioblastoma patients [3].

APC is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain APC status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

APC is altered in 1.98% of central nervous system embryonal neoplasm patients [3].

APC is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain APC status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

APC is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

APC is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

APC is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain APC status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

APC is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain APC status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

APC is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain APC status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

APC is altered in 65.55% of colorectal carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 11.81% of malignant solid tumor patients [3].

APC is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains APC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 10.56% of anaplastic oligodendroglioma patients [3].

APC is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 9.09% of pineoblastoma patients [3].

APC is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

APC is altered in 8.92% of melanoma patients [3].

APC is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 8.59% of esophageal adenocarcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 7.93% of adenocarcinoma of the gastroesophageal junction patients [3].

APC is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains APC status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 6.91% of bladder carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 6.55% of gastric adenocarcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 5.39% of non-small cell lung carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 4.76% of anaplastic pleomorphic xanthoastrocytoma patients [3].

APC is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 3.52% of esophageal squamous cell carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 3.53% of malignant glioma patients [3].

APC is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 3.96% of high-grade glioma, NOS patients [3].

APC is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains APC status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 3.33% of diffuse glioma patients [3].

APC is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 3.17% of anaplastic ependymoma patients [3].

APC is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 3.22% of head and neck carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 3.19% of ovarian carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 2.56% of ependymoma patients [3].

APC is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is altered in 2.59% of pancreatic carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 2.22% of breast carcinoma patients [3].

APC is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 2.18% of sarcoma patients [3].

APC is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is altered in 1.89% of lymphoma patients [3].

APC is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

APC is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains APC status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains APC status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains APC status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains APC status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains APC status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains APC status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains APC status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for gastric squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains APC status and gastric squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains APC status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

APC is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains APC status and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [4].